Eli Lilly shares rose roughly 2% in premarket trading on Thursday after the drugmaker reported encouraging outcomes from a late-stage clinical trial of its investigational obesity medicine retatrutide.
The trial found that adults diagnosed with obesity who received the highest tested dose - 12 milligrams - experienced a mean weight reduction of 28.3% over the 80-week study period. More than 45% of participants in that dose group lost 30% or more of their body weight.
Study participants were adults with obesity or those who were overweight and had at least one weight-related comorbidity. The trial specifically tracked weight change in patients diagnosed with obesity who did not have diabetes.
The company said the results will underpin efforts to seek regulatory approval and could allow for a product launch as soon as next year. The data follow a series of trials that have tested retatrutide at multiple doses and durations.
Retatrutide is distinct in its mechanism because it activates three hormone receptors at once: GLP-1, which suppresses appetite; GIP, which promotes insulin secretion; and glucagon, which supports increased fat burning. Earlier trial data indicated retatrutide produced greater weight loss than Lilly's own injectable Zepbound and compared with Novo Nordisk's Wegovy in prior studies.
Kenneth Custer, president of cardiometabolic health at Eli Lilly, highlighted the clinical significance of the findings, noting that the 30% weight loss threshold historically aligns with outcomes typically associated with bariatric surgery. He characterized the prospect of achieving similar levels of weight loss through a medication as a notable development.
The announcement represents the latest move by Eli Lilly to expand its presence in the growing market for obesity treatments as it advances retatrutide through late-stage development and toward potential regulatory review.
Key takeaways
- Retatrutide at 12 mg produced an average 28.3% weight loss over 80 weeks in patients with obesity without diabetes.
- Over 45% of participants at the highest dose lost 30% or more of body weight, a threshold often linked to bariatric surgery outcomes.
- Results support potential regulatory filings and a possible launch next year, affecting the obesity therapeutics market and related pharmaceutical stocks.
Risks and uncertainties
- Regulatory approval is not guaranteed - the trial results will need to satisfy regulators before a market launch can occur, impacting timelines for the pharmaceutical sector.
- Findings reported are specific to patients with obesity who did not have diabetes, so applicability to other patient groups is limited based on the trial data presented.